Search Results - "Chaudri Ross, Hilary A."

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial by Ellis, Matthew J., Miller, William R., Tao, Yu, Evans, Dean B., Chaudri Ross, Hilary A., Miki, Yasuhiro, Suzuki, Takashi, Sasano, Hironobu

“…Background Expression of aromatase by malignant breast epithelial cells and/or the surrounding stroma implies local estrogen production that could influence…”
Get full text

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics by Ellis, Matthew J., Tao, Yu, Luo, Jingqin, A'Hern, Roger, Evans, Dean B., Bhatnagar, Ajay S., Chaudri Ross, Hilary A., von Kameke, Alexander, Miller, William R., Smith, Ian, Eiermann, Wolfgang, Dowsett, Mitch

“…Background Understanding how tumor response is related to relapse risk would help clinicians make decisions about additional treatment options for patients who…”
Get full text

Optimizing Collection of Adverse Event Data in Cancer Clinical Trials Supporting Supplemental Indications by KAISER, Lee D, MELEMED, Allen S, ABRAMS, Jeffrey S, SCHILSKY, Richard L, PRESTON, Alaknanda J, CHAUDRI ROSS, Hilary A, NIEDZWIECKI, Donna, FYFE, Gwendolyn A, GOUGH, Jacqueline M, BUSHNELL, William D, STEPHENS, Cynthia L, MACE, M. Kelsey

“…Although much is known about the safety of an anticancer agent at the time of initial marketing approval, sponsors customarily collect comprehensive safety…”
Get full text

Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy by Lipton, Allan, Leitzel, Kim, Ali, Suhail M., Demers, Laurence, Harvey, Harold A., Chaudri‐Ross, Hilary A., Evans, Dean, Lang, Raquel, Hackl, Wolfgang, Hamer, Peter, Carney, Walter

“…BACKGROUND Prolonged exposure of breast carcinoma cells in vitro to tamoxifen results in tamoxifen resistance. Tamoxifen‐resistant cells express increased…”
Get full text

Serum TIMP-1 and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen in Metastatic Breast Cancer by LIPTON, Allan, LEITZEL, Kim, CARNEY, Walter, CHAUDRI-ROSS, Hilary A, EVANS, Dean B, ALI, Suhail M, DEMERS, Laurence, HAMER, Peter, BROWN-SHIMER, Sheryl, PIERCE, Karen, GAUR, Victor

“…To determine the effect of elevated serum TIMP-1 on the response of patients with metastatic breast cancer to an aromatase inhibitor versus tamoxifen. Five…”
Get full text

Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer by Souder, Christopher, Leitzel, Kim, Ali, Suhail M., Demers, Laurence, Evans, Dean B., Chaudri‐Ross, Hilary A., Hackl, Wolfgang, Hamer, Peter, Carney, Walter, Lipton, Allan

“…BACKGROUND. Epidermal growth factor receptor (EGFR, HER‐1, and erbB1) is overexpressed in primary breast cancer and had been identified as a poor prognostic…”
Get full text

Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group by Mouridsen, H, Gershanovich, M, Sun, Y, Pérez-Carrión, R, Boni, C, Monnier, A, Apffelstaedt, J, Smith, R, Sleeboom, H P, Jänicke, F, Pluzanska, A, Dank, M, Becquart, D, Bapsy, P P, Salminen, E, Snyder, R, Lassus, M, Verbeek, J A, Staffler, B, Chaudri-Ross, H A, Dugan, M

“…To compare the efficacy and tolerability of tamoxifen with that of letrozole, an oral aromatase inhibitor, with tamoxifen as first-line therapy in…”
Get full text

Letrozole inhibits Tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status by ELLIS, Matthew J, COOP, Andrew, MILLER, William R, SINGH, Baljit, YU TAO, LLOMBART-CUSSAC, Antonio, JÄNICKE, Fritz, MAURIAC, Louis, QUEBE-FEHLING, Erhard, CHAUDRI-ROSS, Hilary A, EVANS, Dean B

“…The biological basis for the superior efficacy of neoadjuvant letrozole versus tamoxifen for postmenopausal women with estrogen receptor (ER)-positive locally…”
Get full text

Abstract P3-06-14: Serum activin A and response to the aromatase inhibibitor (AI) letrozole versus tamoxifen in metastatic breast cancer by Jensen, Meghan, Kang, Ashley, Ali, Suhail M, Leitzel, Kim, Garg, Ashwani, Rogerio, Jaqueline, Chen, David, Hall, Raymond, Hofsess, Scott, Chaudri-Ross, Hilary A, Bade, Nicholas, Carney, Walter P, Lipton, Allan

“…Abstract Introduction: The prognostic and predictive utility of pretreatment serum activin A (TGF-B superfamily ligand) was correlated with the response of…”
Get full text

In Reply by Mouridsen, Henning, Chaudri-Ross, Hilary A.

Get full text

Efficacy of First‐Line Letrozole Versus Tamoxifen as a Function of Age in Postmenopausal Women with Advanced Breast Cancer by Mouridsen, H., Chaudri‐Ross, H.A.

“…Learning Objectives After completing this course, the reader will be able to: Identify those patients in both age groups who responded most favorably to…”
Get full text

Superiority of Letrozole to Tamoxifen in the First‐Line Treatment of Advanced Breast Cancer: Evidence from Metastatic Subgroups and a Test of Functional Ability by Mouridsen, H., Sun, Y., Gershanovich, M., Perez‐Carrion, R., Becquart, D., Chaudri‐Ross, H.A., Lang, R.

“…Learning Objectives After completing this course, the reader will be able to: Identify which advanced breast cancer patients in the three subsets studied (with…”
Get full text

Aromatase inhibitors: treatment of advanced breast cancer by Panasci, L C

Get full text

Letrozole in second-line therapy of advanced breast cancer: more questions than answers by Mackey, J R, Joy, A A

Get full text